Fig. 1From: Bevacizumab dose adjustment to improve clinical outcomes of glioblastomaDifferent levels of VEGFA expression in two human cohorts, in vitro and in xenograft mice. Analysis of VEGFA mRNA expression in gliomas grouped according to histological type and grade a by transcriptomic technologies (TCGA cohort, n = 981) and b by QRT-PCR (our cohort, n = 101). Patients were stratified into 2 groups based on VEGFA expression values: high (green) and low (brown). c Representative images from the immunohistochemical (IHC) analysis of VEGFA in patient tissue microarrays (TMAs). Samples from epileptic patients were used as controls. Scale bar, 300 μm. d Quantification of the IHC analysis of VEGFA expression in our cohort. Staining was scored as follows: 0 = rare, 1 = localized, and 2 = diffuse. Data are expressed as the percentage of the number of positive cases/total number of specimens. e VEGFA serum concentration (pg/ml) prior to surgery in GBM and LGG. Healthy donors were used as controls. Student’s t test **P < 0.01. f Ten glioma cell lines were analyzed for the secretion of VEGFA to the extracellular media at 72 h by ELISA (cells were seeded at 1500 cells/well as a starting culture density). g Basal VEGFA mRNA expression from 10 glioma cell lines quantified by QRT-PCR. Data represent the mean ± S.D. of two independent experiments performed in triplicates. h Representative IHC images of sections obtained from brain intracranial xenografts using anti-VEGFA and anti-human vimentin. Scale bar, 100 μmBack to article page